Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials

Context Most guidelines for treatment of hypertension including the Joint National Committee-7 recommend a blood pressure (BP) goal of <140/90 mm Hg for hypertensive patients and a more aggressive goal of <130/80 mm Hg for patients with coronary artery disease (CAD), based largely on expert consensus. Objective To evaluate the BP targets in patients with CAD Data Sources PUBMED, EMBASE and CENTRAL Study Selection: Randomised clinical trials (RCTs) of antihypertensive therapy in patients with CAD, enrolling at least 100 patients, with achieved systolic pressure of <=135 mm Hg in the ‘intensive BP’ group and <=140 mm Hg in the ‘standard BP’ group with follow-up for at least 1 year and evaluating cardiovascular outcomes. Data Extraction The following efficacy outcomes were extracted- all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, heart failure and revascularisation. Results We identified 15 RCTs enrolling 66 504 participants with 276 328 patient-years of follow-up. Intensive BP group (≤135 mm Hg) was associated with a 15% decrease in heart failure rate and 10% decrease in stroke rate, driven largely by trials with a more intensive BP group (≤130 mm Hg), with similar outcomes for death and cardiovascular death and was associated with a 105% increase in the risk of hypotension. More intensive BP group (≤130 mm Hg) was also associated with a reduction in myocardial infarction and angina pectoris. The results were similar in a Bayesian random effects model. In addition, lower seemed to be better (based on regression analysis) for the outcomes of myocardial infarction, stroke, heart failure and perhaps angina. Conclusions The present body of evidence suggests that in patients with CAD, intensive systolic BP control to ≤135 mm Hg and possibly to ≤130 mm Hg is associated with a modest reduction in stroke and heart failure but at the expense of hypotension. Lower was better, although not consistently so for myocardial infarction, stroke, heart failure and perhaps angina. Further trials are needed to prove these findings.

[1]  Jeroen J. Bax,et al.  2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.

[2]  S. Bangalore,et al.  Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials , 2011, Circulation.

[3]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[4]  S. Bangalore,et al.  J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. , 2010, European heart journal.

[5]  C. Cannon,et al.  What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?: Relationship of Blood Pressure and Cardiovascular Events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 Trial , 2010, Circulation.

[6]  Kevin A Peterson,et al.  Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .

[7]  S. Yusuf,et al.  Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study , 2009, Journal of hypertension.

[8]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[9]  S. Hosoda,et al.  Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). , 2009, European heart journal.

[10]  S. Yusuf,et al.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial , 2008, The Lancet.

[11]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[12]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[13]  J. Rouleau,et al.  Effects of Angiotensin-Converting Enzyme Inhibition in Low-Risk Patients Early After Coronary Artery Bypass Surgery , 2008, Circulation.

[14]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[15]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[16]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[17]  G. Mancia,et al.  Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous? , 2006, Annals of Internal Medicine.

[18]  Douglas G Altman,et al.  Bayesian random effects meta‐analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales by D. E. Warn, S. G. Thompson and D. J. Spiegelhalter, Statistics in Medicine 2002; 21: 1601–1623 , 2005, Statistics in medicine.

[19]  E. Lonn,et al.  Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. , 2005, The American journal of cardiology.

[20]  S. Coca,et al.  Effects of low-dose angiotensin II receptor blocker candesartan on cardiovascular events in patients with coronary artery disease. , 2004, American heart journal.

[21]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[22]  P. Poole‐Wilson,et al.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial , 2004, The Lancet.

[23]  Julian P T Higgins,et al.  Controlling the risk of spurious findings from meta‐regression , 2004, Statistics in medicine.

[24]  Morris J. Brown,et al.  British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary , 2004, BMJ : British Medical Journal.

[25]  S. Hosoda,et al.  Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[26]  Eric J Topol,et al.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. , 2004, JAMA.

[27]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[28]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[29]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[30]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[31]  K. Teo,et al.  Long-Term Effects of Cholesterol Lowering and Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) , 2000, Circulation.

[32]  Michael E. Miller,et al.  Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events , 2000, Circulation.

[33]  John S. Scott,et al.  Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. , 2000, Journal of the American College of Cardiology.

[34]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[35]  I. Olkin,et al.  Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement , 1999, The Lancet.

[36]  Jonathan J Deeks,et al.  metan-an alternative meta-analysis command , 1999 .

[37]  B. Magnani,et al.  Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: Results from the Fosinopril in Acute Myocardial Infarction Study , 1998 .

[38]  B. Magnani,et al.  Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. , 1998, American heart journal.

[39]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[40]  Jan A Staessen,et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension , 1997, The Lancet.

[41]  T. Hedner,et al.  Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. , 1992, Blood pressure.

[42]  R. D'Agostino,et al.  Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. , 1991, BMJ.

[43]  R F Galbraith,et al.  A note on graphical presentation of estimated odds ratios from several clinical trials. , 1988, Statistics in medicine.

[44]  J. Cruickshank,et al.  BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.